Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 3, 2015 Report Details ... that Market, its R&D and Sales Potentials ... of cancer-treating medicines? Visiongain,s new report gives you revenue predictions ... you discover financial data, R&D trends, opportunities, interviews and revenue ... analysis you see forecasted sales to 2025 at overall world ...
(Date:9/3/2015)... , Sept. 3,  2015 About Vision ... care products considered for this report are Rx ... These products are primarily used by consumer for ... as Rx lenses and contact lenses require a ... readers are cosmetic products that can be purchased ...
(Date:9/3/2015)... , Sept. 3,  2015 ... human-made bio-artificial devices, which are implanted or ... natural organs. These include artificial heart, kidney, ... as polymers (polyurethane, polysulfone, and porous polypropylene), ... develop artificial organs. These organs are incorporated ...
Breaking Medicine Technology:World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7Vision Care Market in the US 2015-2019 2Global Artificial Organ Market 2015-2019 2
... Medical, Inc. (Nasdaq: SLTM ), the pioneer in ... in aesthetic skin treatments, today announced it has shipped its ... that have helped to build the foundation of Solta Medical ... milestone reflects how much the aesthetic medical device industry has ...
... (Nasdaq: NVAX ) announced today that the company,s ... to prevent respiratory syncytial virus (RSV) infection has been cleared ... no longer on clinical hold.  In November, the company reported ... chemistry, manufacturing and controls (CMC) that has now been resolved. ...
Cached Medicine Technology:Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 2Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 3NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 2NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 3NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 4
(Date:9/4/2015)... ... ... IVF New England, one of the largest and most successful fertility centers ... for women who wish to learn more about their fertility and egg freezing. , ... Elm Street, Manchester, NH from 6PM to 7PM , This hip, casual and informative ...
(Date:9/4/2015)... ... September 04, 2015 , ... A ... Compassion Project. Core Compassion Project is a non-profit organization dedicated to offering ... side effects of cancer treatments and recover their mobility, strength, and range of ...
(Date:9/4/2015)... Wailea, Maui HI (PRWEB) , ... September 04, 2015 , ... ... of the best ways for couples to explore, revitalize and strengthen their ‘couple-ness,’” ... Wietzel and his team at Four Seasons Resort Maui, the island’s only Forbes Five ...
(Date:9/4/2015)... ... , ... The USC Eye Institute is proud to announce that the ... residents and staff are honored to have contributed to the success of our program. ... program. Our faculty places a high priority on our educational programs in training the ...
(Date:9/4/2015)... ... ... Lalonde Gordon ran a 44.64 seconds scorcher in the third and final ... meters final, with an impressive 44.89 seconds at the 2015 North American, Central American ... August 2015. The 44.64 time is a new NACAC Championship record. , Recent ...
Breaking Medicine News(10 mins):Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3
... , ORLANDO, Fla., Dec. 8 Vestagen Technical ... textile arena with the introduction of the first of ... Orlando based company will provide apparel and textile products ... can occur. Vestex, designed exclusively for the healthcare market, ...
... , SAN DIEGO, Dec. 8, 2009 Amylin Pharmaceuticals, ... Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 1:35 ... Daniel M. Bradbury, president and chief executive officer of Amylin ... be webcast, and a recording will be made available following the ...
... the 2010 AIUM Annual Convention and Preconvention Program, the ... to all disciplines of medical ultrasound, to be held ... Annual Convention focuses on emerging applications and unique opportunities ... ultrasound continues to advance and expand into new arenas. ...
... T-cell lymphopenia, researchers say , TUESDAY, Dec. 8 (HealthDay ... T-cell lymphopenia, a blood disorder that affects the immune ... -- an abnormally low level of white blood cells ... of immunodeficiency. , "Consequently, many infants with severe T-cell ...
... flu complications such as pneumonia , TUESDAY, Dec. ... widely used influenza drug Tamiflu prevents pneumonia or other ... the flu, a new review contends. , Claims about ... have influenced governments worldwide to stockpile Tamiflu (oseltamivir) as ...
... , SAN FRANCISCO, Dec. 8 Quantros, ... industry, has published a whitepaper addressing the ramifications for ... Act of 2005 (PSQIA), the legislation that authorized the ... for healthcare providers contemplating participation in a PSO, ...
Cached Medicine News:Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 2Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 3Health News:AIUM gears up for 2010 Annual Convention in San Diego, California 2Health News:DNA Test May Detect Immune Disorder in Infants 2Health News:Review Questions Tamiflu's Effectiveness 2Health News:Patient Safety Organization (PSO) Participation: What Every Provider Needs to Know 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: